Transport properties of pancreatic cancer describe gemcitabine delivery and response - Wikidata - wikimedia - TriplyDB

Transport properties of pancreatic cancer describe gemcitabine delivery and response

Transport properties of pancreatic cancer describe gemcitabine delivery and response

http://www.wikidata.org/entity/Q37679971

about

Integrated PK-PD and agent-based modeling in oncology Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN Understanding Drug Resistance in Breast Cancer with Mathematical Oncology Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression.Development of a sampling-based global sensitivity analysis workflow for multiscale computational cancer models Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines.Pancreatic cancer and FOLFIRINOX: a new era and new questions.The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival.MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma Blockade of dual-specificity phosphatase 28 decreases chemo-resistance and migration in human pancreatic cancer cells.Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.In vitro and in vivo antitumor activity of gemcitabine loaded thermosensitive liposomal nanoparticles and mild hyperthermia in pancreatic cancer.Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.Development of a diffusion-based mathematical model for predicting chemotherapy effects.Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer.Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence.Quantitative imaging to evaluate malignant potential of IPMNs.Stromal biology and therapy in pancreatic cancer: a changing paradigm.Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.Matrix control of pancreatic cancer: New insights into fibronectin signaling Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A.Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC.Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients.Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.

P2860

Q27006577-2FFCAC66-EF2B-4A24-BF60-D5D33A708314 Q28548074-3661FE0C-6DAB-406A-9F25-B4A4E7143E2C Q28550211-26DDF24E-FF76-4C29-BC42-92EBF417DE06 Q30235129-3D4DD92E-CC8D-44AA-85D6-5167BEA8F0B7 Q33623176-D6488978-C969-43BC-9D2E-28164B07E084 Q33690336-41E4878D-73A5-4551-B998-9AE482245077 Q33803923-8148C0A3-DA24-43ED-8271-3BA6FCE840E0 Q34267265-AA5B2F98-E182-4B53-BB06-FF2F317C2BF3 Q34537580-97F53528-72BC-44F4-B6CC-923AF3EFF628 Q34701798-1E2C3E60-C4CC-4536-B1DF-59C2EA544E71 Q35674606-3811A097-6419-45D6-A99D-94E2F11FE268 Q35740663-741F07B6-E4A2-4A86-AA78-902F4D2BF38F Q35747497-65045D02-57BA-46B6-A2EE-188B220826AF Q35755386-B9B1C15C-DA07-459B-B13A-A4753B633857 Q35820525-B4F9ADEA-455B-4AB7-ACD0-5BACA904770B Q35852437-B4581977-B17C-4053-BD03-45B784CA1C4B Q35891112-FC421521-AA50-4B0F-9EE5-6A3CCF657ADC Q35912798-AB6B63FB-02FE-4224-A36F-CEFFBA0E69C8 Q36117713-7139C301-133C-4D44-B9B5-5409D3D814BA Q36210934-0DEE19FD-5677-4035-911C-DE7501BB07D6 Q36342657-7BC03666-C951-4D55-96A0-38FB2AA45147 Q36368373-0CB3A804-180D-4BCE-9700-CA96AFB130D1 Q36471409-78363AE6-315F-439A-BEB2-4FC3928C06B7 Q36759077-80BEAAC6-49C6-4BCC-AC30-502421629331 Q36990233-C036D66B-A499-431F-852F-C3547BA30747 Q37176654-ED41E353-CA1D-4478-B80F-7864BC493F70 Q37401414-3B199345-0F07-4349-B756-74F535592979 Q37616743-80C8C3FF-DC93-4467-B418-107310813AD0 Q37699125-48227573-5E7C-4F64-988B-EF65AF6BEFA6 Q38494338-F179DD59-CCA3-449D-AEAC-B8B8A9869A59 Q38650842-0C00D359-CEF0-46A5-B178-D20844774BF3 Q38689584-FBB17B69-97A0-4BE8-A2EB-0B5AE18A1630 Q38829774-ADB4E054-9006-4C3D-88F2-BC0E6D0F0AF1 Q38922208-23A3582F-DB15-422A-85F0-4B18F2384870 Q39151780-256986BC-68DA-49D5-97C5-6C95176E97B1 Q42371825-13E563E1-B617-4867-8541-601AAE9C4AF1 Q43379696-D41C53E4-A375-460C-B757-E77329FF45B8 Q46020429-455A50EA-05DE-4A8C-B7F2-6A7AA964A8DF Q47101670-380EED4A-FEE0-4C2B-A8AC-DB1A05E6F0BB Q47123105-897E04F7-0B29-4AA8-9762-4FC6F0A7E604

P2860

Transport properties of pancreatic cancer describe gemcitabine delivery and response

http://www.wikidata.org/entity/Q37679971

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Transport properties of pancreatic cancer describe gemcitabine delivery and response

@en

Transport properties of pancreatic cancer describe gemcitabine delivery and response.

@nl

type

label

Transport properties of pancreatic cancer describe gemcitabine delivery and response

@en

Transport properties of pancreatic cancer describe gemcitabine delivery and response.

@nl

prefLabel

Transport properties of pancreatic cancer describe gemcitabine delivery and response

@en

Transport properties of pancreatic cancer describe gemcitabine delivery and response.

@nl

P1433

Q37679971-BCDCC3B9-20DE-4EB2-96A9-F000E7FF7CEB

P1476

Q37679971-F7554015-1718-43C9-B814-432066574F2A

P2093

Q37679971-00D27F69-5E37-4E1D-AF29-07E53FE06C19

Q37679971-0789AFC9-3A20-4389-9B6A-D577E28F0E33

Q37679971-1441158A-43F7-4790-8150-31462A79F58F

Q37679971-1968CE61-4FBC-4639-8B79-8F1E31EE712D

Q37679971-19CB52F8-3498-43DC-A0F5-9C6441F356C1

Q37679971-1E0A44CC-5B3D-4924-A547-2328248ECB41

Q37679971-1E668112-8514-47D2-B5B8-C92DA68A74FC

Q37679971-2119B53C-7B98-44B2-9012-2BB6A2ECEAC7

Q37679971-228241CF-BB4E-43DC-9229-53711D18056B

Q37679971-3674CF5A-A919-4150-9992-6400ACD3381B

P2860

Q37679971-01A64040-F7EB-4E72-9FB3-8EB06A59DFD3

Q37679971-085080C0-432F-4E22-816E-768276FEFF4E

Q37679971-1CD2FAEF-64EF-41F2-BA8B-80BF7AE7A859

Q37679971-2034B087-CAFD-4325-9203-6BC6B19A8843

Q37679971-23D25749-80F8-4F2D-97D2-D9C52BBA63C4

Q37679971-4CCAC72A-1DD8-4E78-B670-3C509F404735

Q37679971-54308988-2AE9-4B38-95F8-FE5925227119

Q37679971-6034B434-AE99-4832-8EC3-A07F1E6D7C3C

Q37679971-67ED3A47-2312-4845-9A22-304850204C67

Q37679971-6A11EA3F-C159-433B-9EC4-70F9B3F3AB8B

P304

Q37679971-082DC4DF-9931-42A2-8B1A-EE9C9D8292F6

P31

Q37679971-A5728273-C9EA-48E4-BBBF-C52A79D24537

P356

Q37679971-7EB83D84-B342-4C42-AFF4-9722D83811E3

P407

Q37679971-FCEBD6A2-463F-46D7-BDCC-6BE4EDE80587

P433

Q37679971-29A28D1C-925B-45ED-A140-853BE82B3929

P478

Q37679971-E111BF8E-4A80-41FD-9571-4BFF94BA1630

P50

Q37679971-5DA7A013-F09F-4605-957F-142535E53AF3

P577

Q37679971-B72A7960-1F90-4275-B5BF-CA9F3D2830A1

P698

Q37679971-B2F77C0A-D935-4887-9263-E98EEBD20C22

P932

Q37679971-59E78AE7-DB2C-4538-B51B-1D76C2553C39

P356

P1433

Journal of Clinical Investigation

P1476

Transport properties of pancreatic cancer describe gemcitabine delivery and response

@en

P2093

Christopher H Crane

http://www.w3.org/2001/XMLSchema#string

Deyali Chatterjee

http://www.w3.org/2001/XMLSchema#string

Eric P Tamm

http://www.w3.org/2001/XMLSchema#string

Eugene J Koay

http://www.w3.org/2001/XMLSchema#string

Gauri R Varadhachary

http://www.w3.org/2001/XMLSchema#string

Haifa Shen

http://www.w3.org/2001/XMLSchema#string

Huamin Wang

http://www.w3.org/2001/XMLSchema#string

James L Abbruzzese

http://www.w3.org/2001/XMLSchema#string

Jason B Fleming

http://www.w3.org/2001/XMLSchema#string

Jeffery E Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Heterogeneity and targeting of pancreatic cancer stem cells

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

Pancreatic cancer

Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors.

Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Frontiers in cancer nanomedicine: directing mass transport through biological barriers

P304

1525-1536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI73455

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

William Plunkett

P577

2014-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24614108

http://www.w3.org/2001/XMLSchema#string

P932

3973100

http://www.w3.org/2001/XMLSchema#string